Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CR-001 |
| Synonyms | |
| Therapy Description |
CR-001 is a tetravalent bispecific antibody targeting PDCD1 (PD-1) and VEGF, which potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 1185). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CR-001 | CR001|CR 001 | PD-L1/PD-1 antibody 136 VEGF Antibody 17 | CR-001 is a tetravalent bispecific antibody targeting PDCD1 (PD-1) and VEGF, which potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 1185). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07335497 | Phase Ib/II | CR-001 | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors (ASCEND) | Not yet recruiting | USA | 0 |